Temozolomide

Temozolomide Reactions 1680, p319 - 2 Dec 2017 Thrombocytopenia and nausea: case report An 8-year-old boy developed thrombocytopenia and nausea during treatment with temozolomide [route and times to reactions onsets stated; not all outcomes stated]. The boy was diagnosed with an anaplastic oligodendroglioma in the frontal lobe with local leptomeningeal involvement and periventricular subcallosal extension, for which he underwent a near total resection and also had a 1p/19q codeletion. He was started on temozolomide 200 mg/m /day for five days every 28 days for a total of 12 cycles. He tolerated the temozolomide therapy well except for the development of thrombocytopenia and minor nausea. The boy’s temozolomide therapy was delayed once for thrombocytopenia, and his nausea was relieved using ondansetron. His tumour was an isocitrate dehydrogenase wild-type tumour, which showed MGMT gene promoter methylation and harboured a BRAF alteration, an ATRX mutation and CHEK1 frameshift mutation. Author comment: "Based on the favorable cytogenetics (but prior to the IDH sequencing, which was only available later), conservative management with [temozolomide] 200 mg/m daily for 5 days every 28 days for 12 cycles was employed. Therapy was well tolerated with one delay for thrombocytopenia and minor nausea relieved with ondansetron." Sorge C, et al. Complete durable response of a pediatric anaplastic oligodendroglioma to temozolomide alone: Case report and review of literature. Pediatric Blood and Cancer 64: e26708, No. 12, Dec 2017. Available from: URL: http://doi.org/10.1002/pbc.26708 - USA 803284351 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Temozolomide

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/temozolomide-Wi0RKG400I
Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-39250-2
Publisher site
See Article on Publisher Site

Abstract

Reactions 1680, p319 - 2 Dec 2017 Thrombocytopenia and nausea: case report An 8-year-old boy developed thrombocytopenia and nausea during treatment with temozolomide [route and times to reactions onsets stated; not all outcomes stated]. The boy was diagnosed with an anaplastic oligodendroglioma in the frontal lobe with local leptomeningeal involvement and periventricular subcallosal extension, for which he underwent a near total resection and also had a 1p/19q codeletion. He was started on temozolomide 200 mg/m /day for five days every 28 days for a total of 12 cycles. He tolerated the temozolomide therapy well except for the development of thrombocytopenia and minor nausea. The boy’s temozolomide therapy was delayed once for thrombocytopenia, and his nausea was relieved using ondansetron. His tumour was an isocitrate dehydrogenase wild-type tumour, which showed MGMT gene promoter methylation and harboured a BRAF alteration, an ATRX mutation and CHEK1 frameshift mutation. Author comment: "Based on the favorable cytogenetics (but prior to the IDH sequencing, which was only available later), conservative management with [temozolomide] 200 mg/m daily for 5 days every 28 days for 12 cycles was employed. Therapy was well tolerated with one delay for thrombocytopenia and minor nausea relieved with ondansetron." Sorge C, et al. Complete durable response of a pediatric anaplastic oligodendroglioma to temozolomide alone: Case report and review of literature. Pediatric Blood and Cancer 64: e26708, No. 12, Dec 2017. Available from: URL: http://doi.org/10.1002/pbc.26708 - USA 803284351 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680

Journal

Reactions WeeklySpringer Journals

Published: Dec 2, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off